XML 28 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:    
Net loss $ (49,499,000) $ (57,420,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 60,000 17,000
Share-based compensation 3,807,000 389,000
Deferred tax assets (69,000) 20,000
Revaluation of convertible preferred stock liability   30,597,000
Amortization of premium on available-for-sale securities 268,000  
Amortization of debt issuance costs 230,000  
Changes in operating assets and liabilities:    
Prepaids and other current assets (3,600,000) (1,918,000)
Other assets   (72,000)
Accounts payable 1,131,000 (520,000)
Accrued expenses 1,428,000 3,447,000
Net cash used in operating activities (46,244,000) (25,460,000)
Cash flows from investing activities:    
Purchases of available-for-sale securities (118,895,000)  
Proceeds from maturities of available-for-sale securities 12,189,000  
Purchases of property and equipment (126,000) (139,000)
Net cash used in investing activities (106,832,000) (139,000)
Cash flows from financing activities:    
Proceeds from issuance of common stock upon public offerings, net of issuance costs 157,680,000  
Proceeds from issuance of common stock upon initial public offering, net of issuance costs   87,691,000
Proceeds from issuance of convertible preferred stock and convertible preferred stock liability, net of issuance costs   20,000,000
Proceeds from issuance of common stock upon stock option exercises 271,000  
Proceeds from issuance of common stock   11,000
Payment of debt issuance costs (161,000)  
Net cash provided by financing activities 157,924,000 107,702,000
Net increase in cash and cash equivalents, and restricted cash 4,848,000 82,103,000
Cash and cash equivalents, and restricted cash at beginning of period 93,360,000 11,257,000
Cash and cash equivalents, and restricted cash at end of period 98,208,000 93,360,000
Components of cash and cash equivalents, and restricted cash:    
Cash and cash equivalents 98,183,000 93,335,000
Restricted cash 25,000 25,000
Cash and cash equivalents, and restricted cash at end of period 98,208,000 93,360,000
Supplemental disclosures of noncash information:    
Issuance of common stock warrant in connection with term loan facility 634,000  
Property and equipment purchases included in accounts payable   55,000
Cash paid for taxes 142,000 106,000
Conversion of convertible preferred stock into common stock at close of initial public offering   49,746,000
Capital contribution related to extinguishment of convertible preferred stock liability   $ 25,595,000
ESPP Purchases    
Cash flows from financing activities:    
Proceeds from issuance of common stock $ 134,000